Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data

The new data on Novo Nordisk's oral semaglutide 25 mg obesity pill showcases significant potential as an alternative treatment for obesity. Medical professionals should take note of its promising results in improving blood glucose levels and achieving weight loss comparable to injectable semaglutide, offering a new option for patients with obesity and related metabolic conditions.